Scientists uncover how glioblastoma cells may survive chemotherapy by hijacking a fertility gene that helps them evade treatment. Researchers hope the breakthrough could prevent relapse and lead to ...
Research by University of Sydney scientists has uncovered a mechanism that may explain why glioblastoma returns after ...
ANC elders push back against Mashatile presidential endorsement Focalistic faces backlash over song praising alleged criminal ...
The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's Enhertu in combination with Roche ...
Pfizer's oral HER2 inhibitor Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive ...
The combination was well tolerated: no treatment-related deaths occurred, and only 6% (2 patients) were discontinued due to ...
AFSOS 2025 introduced the first European reference for photobiomodulation, outlining the evidence, dosing, and clinical use in supportive cancer care.
7don MSN
Aza–ven combination outperforms standard care in AML patients eligible for intensive chemotherapy
In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen ...
Akeso, Inc. (9926.HK) (Akeso or the Company) announced the presentation of a Phase II clinical study that included a ...
Overall, tucatinib add-on to first-line maintenance therapy for HER2-positive metastatic breast cancer delayed progression by ...
In the phase 2 Smart Stop trial, researchers investigated the feasibility of achieving durable complete responses in DLBCL without the use of chemotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback